FIELD: pharmaceutics.
SUBSTANCE: invention relates to drug delivery systems or to its pharmaceutically acceptable salts that are represented by formulas (XXX), (XXXII), (XXXIV), (XXXVI), (XXXVIII) given in the formula of the invention, in which a drug is a biologically active component containing at least one primary or secondary amino group or ring nitrogen atom in azaheteroaryl ring; and R4 is methyl, ethyl, propyl, isopropyl, 1-methylcyclopropyl or methoxymethyl.
EFFECT: new drug delivery systems are developed that provide delayed release of biologically active components for therapeutically significant applications.
5 cl, 9 dwg, 27 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIFUNCTIONAL CYTOTOXIC AGENTS | 2015 |
|
RU2669807C2 |
| CYTOTOXIC PEPTIDES AND ANTIBODY-DRUG CONJUGATES THEREOF | 2012 |
|
RU2586885C2 |
| CALICHEAMICIN DERIVATIVES AND THEIR ANTIBODY-DRUG CONJUGATES | 2018 |
|
RU2732568C1 |
| COMPOUND BASED ON PYRROLAMIDOPYRIDONE, METHOD OF ITS PREPARATION AND USE | 2020 |
|
RU2809596C2 |
| PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDES | 2010 |
|
RU2553656C2 |
| DERIVATIVES OF 2-AMINOPYRIDINE OR 2-AMINOPYRIMIDINE AS CYCLIN-DEPENDENT KINASE INHIBITORS | 2019 |
|
RU2762557C1 |
| 2-AMINOPYRIDINE OR 2-AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | 2019 |
|
RU2790006C2 |
| ANTIBODY AND DRUG CONJUGATES AS A SPLICING MODULATOR AND METHODS OF THEIR USE | 2019 |
|
RU2799438C2 |
| DANTROLENE PRODRUGS AND METHODS OF THEIR USE | 2018 |
|
RU2815017C2 |
| ANTIBODY-DRUG CONJUGATE TARGETING TROP2, AND METHOD FOR PREPARING AND USING SAME | 2020 |
|
RU2822663C1 |
